

REMARKS

Claims 31 - 75 and 78 -87 are now in this application. Claims 1 - 14 and 16 - 30 are rejected. Claims 1 - 14, and 16 - 30 were cancelled by the Amendment filed June 7, 2004. Claim 15 is previously cancelled. Claims 76 and 77 are cancelled herein. The new claims added by the Amendment of June 7, 2004 have been amended so as to be drawn to transdermal or transmucosal compositions, instead of morphine alkaloid acid addition salt compositions, which the Examiner indicated in the communication to which this Supplemental Amendment is responsive to be a different invention from that as originally claimed. The claims presented herein are deemed to be properly drawn to the same invention as the claims of the original application and to address matters of form unrelated to substantive patentability issues that existed in previous claims 1 - 14 and 16 - 30, as well as overcome 35 U.S.C. 112, first and second paragraph rejections of previous claims 1 - 14 and 16 - 30. All of the Examiner's bases for rejection under 35 U.S.C. 112, first and second paragraphs, as set forth in numbered paragraphs 3 - 112 of the Office Action dated February 6, 2004, are believed to be successfully overcome by the present set of amended claims. Other formal matters are also attended to that were not addressed by the Examiner and accordingly are considered unrelated to substantive patentability issues. No new matter is added.

All of the claims presented herein are supported by the original specification and claims. Claims 76 and 77 are cancelled herein inasmuch as the subject matter of those claims is incorporated in currently amended claim 31. Applicants maintain that structural formula I supports all of the members of the Markush sub-group of morphine alkaloids according to new claim 31.


The fee for new claims added by the previous Amendment was determined in the Amendment and authorization to charge the fee therefore was made therein. No further claims are added by this Supplemental Amendment, therefore no further claims fees are presently due.

This Supplemental Amendment is being filed within the original one month period for response. Accordingly, no extension of time is required and no extension fee is presently due.

In light of the foregoing, the application is now believed to be in proper form for allowance of all claims and notice to that effect is earnestly solicited. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-1250.

Respectfully submitted,

JORDAN AND HAMBURG LLP

By 
C. Bruce Hamburg
Reg. No. 22,389
Attorney for Applicants

Jordan and Hamburg LLP
122 East 42nd Street
New York, New York 10168
(212) 986-2340